SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly shares are drawing attention for continued weakness and underperformance amid a broader pullback in space stocks, with traders debating whether SpaceX is pulling capital away from smaller companies and compressing sector valuations. Some see the decline as excessive given Fireflys contracts and long-term lunar ambitions, while others are frustrated by the stocks inability to hold gains.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Oppenheimers upgrade to Outperform, citing rising contract values and early monetization of agentic AI traffic, is driving attention to Fastly. Traders are broadly reacting bullishly to the growth thesis and rally, while some question how much AI traffic will translate into revenue and warn that the stocks sharp swings may fade.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

GEOM is drawing attention around its proposed platform for tokenizing oil and mineral assets and royalties, with traders linking its prospects to Greenland Energy (GLND) and anticipating platform or partner developments. Bullish holders see an early real-world-asset opportunity, while skeptics cite the tokens decline, thin liquidity, and uncertainty about execution.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royces pullback and repeated weakness are drawing attention, with traders split between frustration over the decline and buying dips on a bullish long-term view. Supporters point to aviation and defense demand, Indias proposed fighter-engine partnership, and potential data-center and SMR growth, while some remain wary of macro headwinds and the still-unconfirmed hyperscaler deal.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgans upcoming third-quarter earnings report is a main focus, with traders also debating a pullback in bank stocks amid rising Treasury yields and concerns about loan growth, deposit costs and credit. Some see the weakness as an opportunity ahead of results, while others remain cautious about pressure on the sector.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs agreement to acquire low-band spectrum and its plans to expand Starlink Mobile have driven concern that it could become a future competitor to T-Mobile and other wireless carriers. Traders debate whether that threat warrants the sharp selloff or is being overstated given the time and infrastructure needed to build a competing network, with many viewing the drop as a buying opportunity.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transoceans new offshore contract and the addition of the Equinor agreement to firm backlog are drawing attention, alongside progress toward its Valaris merger. Traders see growing backlog and high oil prices as bullish, but many are frustrated that RIG has struggled to respond; claims that heavy shorting is suppressing the stock remain speculation.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

Golds recent pullback and choppy rebound dominate discussion, with traders linking pressure on the metal to a stronger dollar, elevated Treasury yields, and hawkish Fed expectations. Some see a potential bottom and point to safe-haven and central-bank demand, while others warn the decline may continue.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Traders are focused on Aerodromes planned merger with Velodrome and expansion into Ethereum and other chains, alongside buybacks and token-locking they believe could support AEROs value. Sentiment is largely bullish, though some question rollout delays and continued token emissions as the price tests resistance.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A strong, high-volume rally is being attributed by traders to anticipation of founder Patrick Soon-Shiongs Piper Sandler fireside chat and potential trial updates; speculation about a partnership is circulating but remains unconfirmed. The community is also debating whether high short interest could amplify the move, while pointing to ANKTIVA and possible bladder-cancer label expansion as longer-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

India’s Eris launches $14 monthly generic Ozempic shot, among cheapest globally

India’s Eris Lifesciences on Friday launched one of the most affordable versions of Ozempic so far, with the lowest dosage of generic semaglutide starting at 1,290 rupees ($13.8) per month. Launch under the brand Sundae in India for diabetes, with lowest dose of a Sundae vial, at 2 mg. Natco Pharma, Eris’ partner for the semaglutide launch, priced its lowest 2 mg dose at 1,290 rupees a month. Eris also plans to launch a pen device version of Sundae in April, in three dosages. The lowest 2 mg dose will cost 4,000 rupees per month and the highest 8 mg dose 4,500 rupees per month. Eris is among dozens of Indian drugmakers that are launching generic semaglutide as Danish drugmaker Novo Nordisk’s semaglutide patent is set to expire on March 20. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India Larger peer Dr Reddy’s is expected to launch on Saturday. Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.

Eris Lifesciences, Natco Pharma ink pact on Semaglutide

Eris Lifesciences has forged a strategic partnership with Natco Pharma for commercialisation of semaglutide in India.

Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India

… strategic partnership with Natco Pharma Limited for the commercialisation … Natco Pharma has received approval from the Central Drugs Standard … Bulls Keywords ErisLifesciences INE406M01024 Pharmaceuticals Partnership NatcoPharma Semaglutide IndiaLaunch

Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in India

Shares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco rose over 6% to its highest level since January 8, while Eris gained nearly 4%, marking its third straight session of gains.

Eris Lifesciences partners Natco to commercialise semaglutide

Eris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes and obesity management. By combining Eris’s strong commercial network with Natco’s proven production capabilities, the alliance expands Eris’s diabetes care portfolio with a high-impact, next-generation treatment.

Eris Lifesciences/Natco Pharma partner on semaglutide for India

Natco Pharma has received regulatory approval in India, paving the way for a launch in March 2026

Brief India: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY and more

In this briefing: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update 1. Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Overall B2C GOV grew 49% YoY (8.6% QoQ) to reach INR 181.2bn (in-line) Consolidated adj EBITDA losses stood at INR7.1bn (in-line) Food delivery (FD) GOV grew 20.5% YoY to INR 89.6bn (HSIE: INR 88bn) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY and more

In this briefing: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update Union Budget 2026- What We like and What We Don't 1. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Medical Community joins forces on Republic day to address the Silent Crisis of Hypertension at One India Conclave

• Unveils India’s First Hypertension Anthem • National Doctors’ Movement Gains Momentum to Bridge the Diagnosis-to-Control Gap Across India MUMBAI, India, Jan. 27, 2026 /PRNewswire/ — Marking the 77th Republic Day with a call for national health unity, Eris Lifesciences hosted the One India Conclave to address the growing crisis of hypertension in the country. […]

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Current Price	1,175.00
Prev Close	1,162.00
Open	1,155.00
Dividend Yield	0.00%
50-Day Moving Average	1,297.66
Beta	0.03
Avg. Volume	94,161.76
PE Ratio	24.90

52-Week High	1,740.00
52-Week Low	1,141.00
Market Capitalization	159.43B
EPS (Annual)	45.33
Price to Book	4.16
Revenue Per Employee	10.17M

Feed

News

Sentiment

Fundamentals

Info

ERIS.NSE Fundamentals